MacroGenics to Present Pre-Clinical Data on MGD006 at 26 th EORTC-NCI-AACR Symposium ROCKVILLE, Md. , October 30, 2014 - MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the

ROCKVILLE, Md. , October 28, 2014 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX) today announced that on Tuesday, November 11, 2014 , the Company will release its financial results for the quarter ended September 30, 2014 . The Company's management team will host a conference call discussing

ROCKVILLE, Maryland and OSAKA, Japan , Sept. 29, 2014 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (NASDAQ: MGNX) and Takeda Pharmaceutical Company Limited jointly announced today that they have entered into a collaboration agreement to develop and commercialize up to four product candidates.

ROCKVILLE, Md. , Aug. 6, 2014 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, today announced that Scott

First DART(R) Molecule in Human Clinical Trial and Second DART Molecule Expected to Enter Clinic by End of Year

ROCKVILLE, Md. , July 29, 2014 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX) today announced that on Tuesday, August 5, 2014 , the Company will release its financial results for the quarter ended June 30, 2014 . The Company's management team will host a conference call discussing the

Triggers $5M Milestone Payment From Servier

MGD006 Represents the First DART(R) Molecule to Enter the Clinic

Option-based collaboration around MGD010 product candidate Incorporates MacroGenics' proprietary DART technology for bi-specific targeting of CD32B and CD79B MacroGenics has option to co-promote in the United States MacroGenics may participate in funding late-stage development in exchange for North

ROCKVILLE, Md. , May 7, 2014 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, today announced that Scott Koenig

Clinical study of first DART, MGD006, to commence in Second Quarter 2014 Phase 3 margetuximab gastroesophageal "MAGENTA" study poised for initiation in second half 2014 ROCKVILLE, Md. , May 6, 2014 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company

ROCKVILLE, Md. , May 5, 2014 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and identifying innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, today announced the presentation

ROCKVILLE, Md. , April 30, 2014 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, today announced that it has

ROCKVILLE, Md. , April 29, 2014 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX) today announced that on Tuesday, May 6, 2014 , the Company will release its financial results for the quarter ended March 31, 2014 . The Company's management team will host a conference call discussing the Company's

ROCKVILLE, Md. , April 28, 2014 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and identifying innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, today announced that it will

ROCKVILLE, Md. , April 6, 2014 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and identifying innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, today announced the

ROCKVILLE, Md. , April 1, 2014 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, today announced that Jim

DART Product Candidate Is Being Developed for Treatment of Colorectal Cancer

-- Six Immuno-Oncology Clinical Programs Projected by End of 2015 -- -- Cash Runway Extends Into 2017 -- ROCKVILLE, Md. , March 20, 2014 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal

ROCKVILLE, Md. , March 13, 2014 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX) today announced that on Thursday, March 20, 2014 , the Company will release its financial results for the year ended December 31, 2013 .  The Company's management team will host a conference call discussing the

ROCKVILLE, Md. , March 6, 2014 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX) today announced that its Board of Directors is increasing its size from seven to eight members and that Matthew Fust has been appointed to fill the vacancy. Mr. Fust joins the Board and becomes Chairman of its Audit

ROCKVILLE, Md. , March 3, 2014 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, today announced that Jon

ROCKVILLE, Md. , Feb. 12, 2014 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and identifying innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, today announced the pricing of

ROCKVILLE, Md. , Feb. 10, 2014 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and identifying innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, today announced that it has

Successful Advancement of Lead DART Molecule and Option Exercise Triggers $20 Million in Payments MacroGenics Retains Full Rights to MGD006 in Multiple Major Markets ROCKVILLE, Md. and SURESNES, France , Feb. 5, 2014 (GLOBE NEWSWIRE) -- MacroGenics, Inc.